Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: A randomised controlled open-label trial

The Lancet Global Health

Volumn 2, Issue 12, 2014, Pages e727-e736

  Homsy, Jaco ^a,c   Dorsey, Grant ^b   Arinaitwe, Emmanuel ^d   Wanzira, Humphrey ^d   Kakuru, Abel ^d   Bigira, Victor ^d   Muhindo, Mary ^b   Kamya, Moses R ^e   Sandison, Taylor G ^f   Tappero, Jordan W ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^e MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ANTIINFECTIVE AGENT;

ANEMIA; ARTICLE; BODY TEMPERATURE DISORDER; BREAST FEEDING; CHILD; DRUG EFFICACY; DRUG SAFETY; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALARIA; NEUTROPENIA; OBSERVATIONAL STUDY; OPEN STUDY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HIV INFECTIONS; INFANT; MALE; UGANDA;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALARIA; MALE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA;

EID: 84918794747     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70329-8     Document Type: Article

References (51)

1. Co-trimoxazole prophylaxis for HIV-exposed and HIV- infected infants and children: Practical approaches to implementation and scale up 2009, WHO, UNICEFUNICEF, World Health Organization, Geneva.
2. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach 2013, WHO, World Health Organization, Geneva. 2013 edn.
3. Aizire J, Fowler MG, Wang J, et al. Extended prophylaxis with nevirapine and co-trimoxazole among HIV-exposed uninfected infants is well tolerated. AIDS 2012, 26:325-333.
4. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007, 21:2059-2066.
5. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364:1428-1434.
6. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005, 192:1823-1829.
7. Walker AS, Mulenga V, Ford D, et al. The impact of daily co-trimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007, 44:1361-1367. the CHAP Team.
8. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004, 364:1865-1871. the CHAP trial team.
9. Kalembo FW, Zgambo M Loss to followup: a major challenge to successful implementation of prevention of mother-to-child transmission of HIV-1 programs in sub-Saharan Africa. ISRN AIDS 2012, 2012:589817.
10. Jones SA, Sherman GG, Varga CA Exploring socio-economic conditions and poor follow-up rates of HIV-exposed infants in Johannesburg, South Africa. AIDS Care 2005, 17:466-470.
11. Nielsen K, Bryson YJ Diagnosis of HIV infection in children. Pediatr Clin North Am 2000, 47:39-63.
12. WHO recommendations on the diagnosis of HIV infection in infants and children 2010, WHO, World Health Organization, Geneva.
13. Menzies NA, Homsy J, Chang Pitter JY, et al. Cost-effectiveness of routine rapid human immunodeficiency virus antibody testing before DNA-PCR testing for early diagnosis of infants in resource-limited settings. Pediatr Infect Dis J 2009, 28:819-825.
14. Ubesie AC Pediatric HIV/AIDS in sub-Saharan Africa: emerging issues and way forward. Afr Health Sci 2012, 12:297-304.
15. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013 2013, UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva.
16. World Malaria Report 2012 2012, WHO, World Health Organization, Geneva.
17. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011, 342:d1617.
18. Carneiro I, Roca-Feltrer A, Griffin JT, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One 2010, 5:e8988.
19. Jagannathan P, Muhindo MK, Kakuru A, et al. Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. Malar J 2012, 11:435.
20. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006, 75:219-225.
21. Gasasira AF, Kamya MR, Ochong EO, et al. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J 2010, 9:177.
22. Malamba S, Sandison T, Lule J, et al. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am J Trop Med Hyg 2010, 82:766-771.
23. HIV and infant feeding: update based on the technical consultation held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV infections in pregnant women, mothers and their infants, Geneva, Switzerland 25-27 Oct, 2006 2007, WHO, UNICEFUNICEF, UNPFUNPF, UNAIDSUNAIDS, World Health Organization, Geneva.
24. Uganda National Integrated ART-PMTCT Guidelines 2012 2012, Uganda Ministry of Health, Ministry of Health, Kampala. 2nd edn.
25. Guidelines on HIV and Infant Feeding 2010: Principles and recommendations for infant feeding in the context of HIV and a summary of evidence 2010, WHO, World Health Organization, Geneva.
26. Uganda National Policy of HIV Counselling and Testing 2005, Uganda Ministry of Health, Ministry of Health, Kampala.
27. Roll Back Malaria Dept. Guidelines for the treatment of malaria 2006, WHO, World Health Organization, Geneva.
28. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009, 49:1629-1637.
29. ICH harmonised tripartite guideline-clinical safety data management: definitions and standards for expedited reporting. E2A 1994, 12. International Conference on Harmonisation (ICH), International Conference on Harmonisation, Geneva.
30. Yeka A, Gasasira A, Mpimbaza A, et al. Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop 2012, 121:184-195.
31. Mermin J, Lule J, Ekwaru JP, et al. Co-trimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005, 19:1035-1042.
32. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006, 41:504-508.
33. Chatterjee A, Bosch RJ, Hunter DJ, Fataki MR, Msamanga GI, Fawzi WW Maternal disease stage and child undernutrition in relation to mortality among children born to HIV-infected women in Tanzania. J Acquir Immune Defic Syndr 2007, 46:599-606.
34. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007, 26:519-526. for the ZVITAMBO Study Group.
35. Ladeia-Andrade S, Ferreira MU, de Carvalho ME, Curado I, Coura JR Age-dependent acquisition of protective immunity to malaria in riverine populations of the Amazon Basin of Brazil. Am J Trop Med Hyg 2009, 80:452-459.
36. Barragan A, Kremsner PG, Weiss W, Wahlgren M, Carlson J Age-related buildup of humoral immunity against epitopes for rosette formation and agglutination in African areas of malaria endemicity. Infect Immun 1998, 66:4783-4787.
37. Guinovart C, Dobaño C, Bassat Q, et al. The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial. PLoS One 2012, 7:e32362.
38. Odhiambo FO, Hamel MJ, Williamson J, et al. Intermittent preventive treatment in infants for the prevention of malaria in rural western Kenya: a randomized, double-blind placebo-controlled trial. PLoS One 2010, 5:e10016.
39. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009, 374:1533-1542.
40. Green MD, van Eijk AM, van Ter Kuile FO, et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis 2007, 196:1403-1408.
41. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking co-trimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 2011, 203:464-472.
42. Petersen E In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. Trans R Soc Trop Med Hyg 1987, 81:238-241.
43. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006, 367:1256-1261.
44. Namukwaya Z, Mudiope P, Kekitiinwa A, et al. The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 2007 to May 2009. J Acquir Immune Defic Syndr 2011, 56:69-75.
45. Coutsoudis A, Coovadia HM, Kindra G Time for new recommendations on co-trimoxazole prophylaxis for HIV-exposed infants in developing countries?. Bull World Health Organ 2010, 88:949-950.
46. Coutsoudis A, Kindra G, Esterhuizen T Impact of co-trimoxazole prophylaxis on the health of breast-fed, HIV-exposed, HIV-negative infants in a resource-limited setting. AIDS 2011, 25:1797-1799.
47. Kamya MR, Byakika-Kibwika P, Gasasira AF, et al. The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa. Future Virol 2012, 7:699-708.
48. Bigira V, Kapisi J, Clark TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 2014, 11:e1001689.
49. González R, Ataíde R, Naniche D, Menéndez C, Mayor A HIV and malaria interactions: where do we stand?. Expert Rev Anti Infect Ther 2012, 10:153-165.
50. Osterbauer B, Kapisi J, Bigira V, et al. Factors associated with malaria parasitaemia, malnutrition, and anaemia among HIV-exposed and unexposed Ugandan infants: a cross-sectional survey. Malar J 2012, 11:432.
51. Zachariah R, Harries AD, Luo C, Bachman G, Graham SM Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. Lancet Infect Dis 2007, 7:686-693.